Experimental injection targets tumors directly in new cancer trial

NCT ID NCT05901285

Recruiting now Disease control Sponsor: Vaxiion Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 2 times

Summary

This early-phase study tests an experimental drug called VAX014, which is injected directly into tumors to kill cancer cells. It is for adults with advanced solid tumors that have not responded to standard treatments. The study will first find a safe dose of VAX014 alone, then test it combined with an immunotherapy drug (nivolumab or pembrolizumab). The goal is to see if the treatment is safe and can shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR ADVANCED SOLID TUMORS APPROPRIATE FOR TREATMENT WITH EITHER NIVOLUMAB OR PEMBROLIZUMAB

Contacts and locations

Locations

Atlantic Health System
RECRUITING

Morristown, New Jersey, 07960, United States
Cleveland Clinic
RECRUITING

Cleveland, Ohio, 44195, United States
Dana Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
Dartmouth Cancer Center
RECRUITING

Lebanon, New Hampshire, 03756, United States
George Washington University
RECRUITING

Washington D.C., District of Columbia, 20052, United States
Melanoma & Skin Cancer Institute
NOT_YET_RECRUITING

Denver, Colorado, 80113, United States
Sarah Cannon Research Institute at HealthONE
RECRUITING

Denver, Colorado, 80218, United States
University of Arizona Cancer Center
RECRUITING

Tucson, Arizona, 85719, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.